Researchers examine the strengths and shortcomings of the current European Alliance of Associations for Rheumatology definition for difficult-to-treat rheumatoid arthritis.
Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.